TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31256093

Group type: EXPERIMENTAL
Intervention: NeuroDRIVE intervention
Number of subjects: 17

Group type: COMPARATOR
Intervention: Wait-listed control group
Number of subjects: 17
Study: 27836404

Group type: EXPERIMENTAL
Intervention: Octyl cyanoacrylate skin adhesive
Number of subjects: 109

Group type: COMPARATOR
Intervention: Subcuticular suture
Number of subjects: 109
Study: 25884724

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (two different daily doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sun exposure (two different patterns)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23630052

Group type: EXPERIMENTAL
Intervention: Beta-alanine (65 mg · kg ‐ 1BM)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Beta-alanine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (dextrose monohydrate)
Number of subjects: 16
Study: 21366944

Group type: EXPERIMENTAL
Intervention: Passive leg raising (PLR)
Number of subjects: 30
Study: 19515873

Group type: EXPERIMENTAL
Intervention: Folic acid (1 mg), vitamin B(12) (400 microg), vitamin B(6) (10 mg) daily
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 15673860

Group type: COMPARATOR
Intervention: ondansetron 4 mg IV
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: dolasetron 12.5 mg IV
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: dolasetron
Number of subjects: 92
Study: 12629227

Group type: EXPERIMENTAL
Intervention: Whiplash injury
Number of subjects: 181

Group type: COMPARATOR
Intervention: Ankle injury
Number of subjects: 181
Study: 10555719

Group type: EXPERIMENTAL
Intervention: Monthly retrospective written feedback mailed to residents detailing their missed immunization opportunities and appointment failure rates over a 12‐month period.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups with fewer than 2 visits during the second year of life
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups with 2 visits during the second year of life
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups with more than 2 visits during the second year of life
Number of subjects: 32
Study: 8677278

Group type: EXPERIMENTAL
Intervention: Hydrocortisone phonophoresis (10% hydrocortisone acetate, ultrasound at 1.0 W/cm2 for 5 minutes)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control treatment (ultrasound alone)
Number of subjects: 16
Study: 1925046

Group type: EXPERIMENTAL
Intervention: Skilled teacher model
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Unskilled teacher model
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Skilled peer model
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Unskilled peer model
Number of subjects: 100

Group type: COMPARATOR
Intervention: No model (control group)
Number of subjects: 100
Study: 6315514

Group type: EXPERIMENTAL
Intervention: High fibre diet (51.4 g dietary fibre/24 h)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard dietary advice (12.4 g dietary fibre/24 h)
Number of subjects: 100
Study: 30625398

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) with adjunct antimicrobial photodynamic therapy (aPDT)
Number of subjects: 83
Study: 28642208

Group type: EXPERIMENTAL
Intervention: Imagery-enhanced cognitive behavioral group therapy (IE-CBGT)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Verbally-based cognitive behavioral group therapy (VB-CBGT)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: IE-CBGT
Number of subjects: 96
Study: 25680595

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (ICT) with oxaliplatin 130 mg/m² on day 1 and S1 at 40 mg/m² twice daily on days 1‐14, followed by concurrent chemoradiotherapy (CCRT) (46 Gy, 2 Gy/d with oxaliplatin 130 mg/m² on days 1 and 21 and S1 30 mg/m² twice daily, 5 days per week during radiation therapy) and esophagectomy (arm A)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy (CCRT) followed by esophagectomy without ICT (arm B)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (ICT) with oxaliplatin and S1 (arm A)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy (CCRT) without ICT (arm B)
Number of subjects: 97
Study: 23305613

Group type: EXPERIMENTAL
Intervention: King laryngeal tube (KLT) airway
Number of subjects: 67

Group type: COMPARATOR
Intervention: Basic airway management (bag‐mask ventilation [BMV])
Number of subjects: 67
Study: 21512258

Group type: EXPERIMENTAL
Intervention: Subcutaneous fondaparinux
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intravenous unfractionated heparin (UFH)
Number of subjects: 80
Study: 19039051

Group type: EXPERIMENTAL
Intervention: Microvascular decompression surgery
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Affected trigeminal nerve
Number of subjects: 66

Group type: COMPARATOR
Intervention: Contralateral trigeminal nerve
Number of subjects: 66

Group type: COMPARATOR
Intervention: Normal trigeminal nerves
Number of subjects: 66
Study: 17711768

Group type: EXPERIMENTAL
Intervention: Fluorescence-guided surgical excision
Number of subjects: 51

Group type: COMPARATOR
Intervention: Surgical excision with surgeon‐delineated excision margins
Number of subjects: 51
Study: 16013776

Group type: EXPERIMENTAL
Intervention: FDC formulations containing rifampicin, isoniazid, and ethambutol hydrochloride
Number of subjects: 22
Study: 12204509

Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg and cobalamin 400 microg daily
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 10476895

Group type: EXPERIMENTAL
Intervention: GBA group (polylactide bioabsorbable membrane, DFDBA plus antibiotics)
Number of subjects: 24

Group type: COMPARATOR
Intervention: GB group (polylactide membrane and DFDBA alone)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: GBA group
Number of subjects: 24

Group type: COMPARATOR
Intervention: GB group
Number of subjects: 24
Study: 8945694

Group type: EXPERIMENTAL
Intervention: Rabeneck clinical staging system
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Royce clinical staging system
Number of subjects: 335

Group type: COMPARATOR
Intervention: CD4 count
Number of subjects: 335
Study: 1952442

Group type: EXPERIMENTAL
Intervention: Severe sleep fragmentation (arousal to an auditory stimulus after each minute of sleep)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Normal sleep
Number of subjects: 13
Study: 6299752

Group type: EXPERIMENTAL
Intervention: Mianserin (acute and chronic administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mianserin (acute administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clonidine and Methyldopa
Number of subjects: 0
Study: 31555441

Group type: EXPERIMENTAL
Intervention: Zinc treatment
Number of subjects: 13191
Study: 30272851

Group type: EXPERIMENTAL
Intervention: Probiotic capsule of Bifidobacterium longum and Lactobacillus acidophilus (2 × 10^7 CFU/day)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Prebiotic (10 g/day inulin)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Co-administration of probiotic and prebiotic
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 26386707

Group type: EXPERIMENTAL
Intervention: Metronomic chemotherapy (methotrexate and celecoxib)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Cisplatin chemotherapy
Number of subjects: 87
Study: 24423407

Group type: EXPERIMENTAL
Intervention: Tongue cleaning
Number of subjects: 30

Group type: COMPARATOR
Intervention: No tongue cleaning (Control)
Number of subjects: 30
Study: 22199016

Group type: EXPERIMENTAL
Intervention: New or recurrent myocardial infarction (MI)
Number of subjects: 13608

Group type: EXPERIMENTAL
Intervention: Type 4a MI (peri-percutaneous coronary intervention)
Number of subjects: 13608

Group type: EXPERIMENTAL
Intervention: Type 4b MI (stent thrombosis)
Number of subjects: 13608

Group type: EXPERIMENTAL
Intervention: Any MI
Number of subjects: 13608
Study: 20302615

Group type: EXPERIMENTAL
Intervention: Mindfulness‐Based Cognitive Therapy (MBCT)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Cognitive Psycho‐Education (CPE)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 300
Study: 17090640

Group type: EXPERIMENTAL
Intervention: MA/TE (Megestrol Acetate + Testosterone Enanthate)
Number of subjects: 79

Group type: COMPARATOR
Intervention: MA/PL (Megestrol Acetate + Placebo)
Number of subjects: 79
Study: 16303697

Group type: EXPERIMENTAL
Intervention: Iron supplements (1 mg/kg/d) from 4‐9 mo of age
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Iron supplements from 6‐9 mo
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study: 11991311

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine‐containing wax
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo wax
Number of subjects: 14
Study: 9856716

Group type: EXPERIMENTAL
Intervention: Tenoxicam (2 mg) with lidocaine, 2% epidurally and lidocaine, 1% for local skin infiltration
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group received lidocaine, 2% epidurally and lidocaine, 1% for local skin infiltration
Number of subjects: 1000
Study: 8669876

Group type: EXPERIMENTAL
Intervention: 5 ml of fibrin glue (Tissucol) applied to the wound cavity
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (40 patients who underwent surgery without fibrin glue)
Number of subjects: 40
Study: 2194314

Group type: EXPERIMENTAL
Intervention: gemfibrozil 600 mg twice daily
Number of subjects: 43

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 43
Study: 692548

Group type: EXPERIMENTAL
Intervention: Labeling as hypertensive
Number of subjects: 0

Group type: COMPARATOR
Intervention: General employee population
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Awareness of hypertension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low compliance with treatment
Number of subjects: 0
Study: 29536820

Group type: EXPERIMENTAL
Intervention: 20 mg hydrocortisone
Number of subjects: 54

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 54
Study: 26426276

Group type: EXPERIMENTAL
Intervention: CRT-P ON
Number of subjects: 44

Group type: COMPARATOR
Intervention: CRT-P OFF
Number of subjects: 44
Study: 24103211

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Midazolam (Control)
Number of subjects: 22
Study: 22506692

Group type: EXPERIMENTAL
Intervention: Topical 5% tranexamic acid
Number of subjects: 23

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 23
Study: 20688744

Group type: EXPERIMENTAL
Intervention: Saffron 20 mg/d
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 18494840

Group type: EXPERIMENTAL
Intervention: 15-session case management intervention
Number of subjects: 936

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 936
Study: 15925161

Group type: EXPERIMENTAL
Intervention: Neurolac nerve guide (Polyganics B.V.)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard reconstruction techniques
Number of subjects: 30
Study: 12949718

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg daily for >14 days
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 44
Study: 10566707

Group type: EXPERIMENTAL
Intervention: Sumatriptan 6 mg subcutaneous (s.c.)
Number of subjects: 13
Study: 8678099

Group type: EXPERIMENTAL
Intervention: Cefepime 1 g every 12 hours
Number of subjects: 336

Group type: COMPARATOR
Intervention: Ceftazidime 1 g every 8 hours
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Cefepime (blinded study)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Ceftazidime (blinded study)
Number of subjects: 336
Study: 1985504

Group type: EXPERIMENTAL
Intervention: ORG 9426 at 240 micrograms/kg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: ORG 9426 at 300 micrograms/kg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: ORG 9426 at 75 micrograms/kg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: ORG 9426 at 100 micrograms/kg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: ORG 9426 (up to 5 maintenance doses)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: ORG 9426 (doses used in the study)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: ORG 9426
Number of subjects: 72
Study: 6684719

Group type: EXPERIMENTAL
Intervention: Aztreonam (1 g every 8 hours for 5 to 10 days)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Cefamandole (1 g every 8 hours for 5 to 10 days)
Number of subjects: 21
Study: 31469084

Group type: EXPERIMENTAL
Intervention: Technology-based peer-support intervention program (PIP)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Standard care plus peer support
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group (standard care only)
Number of subjects: 138
Study: 29858418

Group type: EXPERIMENTAL
Intervention: Verum acupuncture and placebo medicine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham acupuncture and real medicine (topiramate)
Number of subjects: 60
Study: 27277941

Group type: EXPERIMENTAL
Intervention: Community-based daycare program
Number of subjects: 3177
Study: 23969994

Group type: EXPERIMENTAL
Intervention: Music intervention (two one-hour sessions a week for four weeks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cooking intervention (two one-hour sessions a week for four weeks)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cooking intervention
Number of subjects: 48
Study: 22085203

Group type: EXPERIMENTAL
Intervention: PSA density (PSAD) for Gleason score 6
Number of subjects: 1516

Group type: EXPERIMENTAL
Intervention: PSA density (PSAD) for Gleason score 3 + 4 = 7
Number of subjects: 1516

Group type: COMPARATOR
Intervention: Clinical stage and number of positive cores for Gleason score 7 to >7
Number of subjects: 1516

Group type: EXPERIMENTAL
Intervention: Tumour volume and serum PSA level per millilitre tumour volume
Number of subjects: 1516
Study: 20001392

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 63

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 63
Study: 18548084

Group type: EXPERIMENTAL
Intervention: Oral patterned entrainment intervention (synthetically patterned orocutaneous pulse trains through a pneumatically controlled silicone pacifier)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (non-treated group)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Oral patterned entrainment intervention
Number of subjects: 31
Study: 15935981

Group type: EXPERIMENTAL
Intervention: High-dose hGH (16 U/d) for nine days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 12796368

Group type: COMPARATOR
Intervention: recombinant human LIF (rhLIF) at doses of 0.25‐16.0 micro g/kg/day or 4.0 micro g/kg three times daily for 7 days
Number of subjects: 74

Group type: COMPARATOR
Intervention: recombinant human LIF (rhLIF) at doses of 0.25‐8.0 micro g/kg/day once daily for 14 days or 4.0 micro g/kg three times daily for 7 days
Number of subjects: 74

Group type: COMPARATOR
Intervention: recombinant human LIF (rhLIF) at doses of >/=4.0 micro g/kg/day
Number of subjects: 74

Group type: COMPARATOR
Intervention: recombinant human LIF (rhLIF) at higher doses
Number of subjects: 74

Group type: COMPARATOR
Intervention: recombinant human LIF (rhLIF)
Number of subjects: 74
Study: 11113984

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 120
Study: 9038496

Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning (two 3 min periods of crossclamping and 2 min of reperfusion, followed by 10 min sustained ischaemia)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning
Number of subjects: 0
Study: 8393398

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg, four times daily)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Cromolyn sodium (2 mg, four times daily)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 3575558

Group type: EXPERIMENTAL
Intervention: Lithium (mean plasma level: 0.65 mmol/l)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29175417

Group type: EXPERIMENTAL
Intervention: TT genotype for the ESR1 (rs2273206) gene
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: CC genotype for the ESRRB (rs1676303) gene
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: C allele for the ESRRB (rs1676303) gene
Number of subjects: 212
Study: 28122787

Group type: EXPERIMENTAL
Intervention: Ketoconazole (KTZ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rifampin (RIF)
Number of subjects: 0
Study: 25973563

Group type: EXPERIMENTAL
Intervention: Freshly reconstituted incobotulinumtoxinA (10 U)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Room temperature-stored incobotulinumtoxinA (10 U)
Number of subjects: 21
Study: 23278618

Group type: EXPERIMENTAL
Intervention: 0.15% ivermectin lotion
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 0.25% ivermectin lotion
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 0.5% ivermectin lotion
Number of subjects: 78

Group type: COMPARATOR
Intervention: Vehicle placebo
Number of subjects: 78
Study: 21664627

Group type: EXPERIMENTAL
Intervention: Intramyocardial CD133(+) bone marrow stem cell transplant
Number of subjects: 35

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting alone
Number of subjects: 35
Study: 18452785

Group type: EXPERIMENTAL
Intervention: CCM ON therapy for 3 months
Number of subjects: 11

Group type: COMPARATOR
Intervention: CCM OFF therapy for 3 months
Number of subjects: 11
Study: 16706693

Group type: EXPERIMENTAL
Intervention: Phototherapy
Number of subjects: 0
Study: 12939429

Group type: EXPERIMENTAL
Intervention: Oral modified cobratoxin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 8
Study: 10845438

Group type: EXPERIMENTAL
Intervention: Ambroxol treatment (30 mg kg(‐1) over the first 5 days)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 102
Study: 9097338

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation intervention (8-week program)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Nonintervention control group
Number of subjects: 28
Study: 8403133

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg orally
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31023843

Group type: EXPERIMENTAL
Intervention: Gefapixant 100 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 28902534

Group type: EXPERIMENTAL
Intervention: Motesanib plus paclitaxel and carboplatin (P/C)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Placebo plus paclitaxel and carboplatin (P/C)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Motesanib plus P/C
Number of subjects: 401

Group type: COMPARATOR
Intervention: Placebo plus P/C
Number of subjects: 401
Study: 25661190

Group type: EXPERIMENTAL
Intervention: Sinupret Forte
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intranasal fluticasone furoate
Number of subjects: 60
Study: 24395447

Group type: COMPARATOR
Intervention: Tamoxifen (TAM) 20 mg daily for 2 years
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Doxorubicin (A) 40 mg/m2 and Cyclophosphamide (C) 500 mg/m2 plus Tamoxifen (ACT)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Doxorubicin (A) and Cyclophosphamide (C) plus Tamoxifen (ACT)
Number of subjects: 129
Study: 22895994

Group type: EXPERIMENTAL
Intervention: Higher-intensity RT
Number of subjects: 54

Group type: COMPARATOR
Intervention: Lower-intensity RT
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 54
Study: 20109118

Group type: EXPERIMENTAL
Intervention: Systematic secondary prevention educational intervention
Number of subjects: 304

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 304
Study: 17100962

Group type: EXPERIMENTAL
Intervention: Hemoclip
Number of subjects: 100

Group type: COMPARATOR
Intervention: Triclip
Number of subjects: 100
Study: 15704611

Group type: EXPERIMENTAL
Intervention: Regression analyses
Number of subjects: 0
Study: 12013158

Group type: COMPARATOR
Intervention: Laser vaporisation
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Loop diathermy excision
Number of subjects: 289
Study: 9449273

Group type: EXPERIMENTAL
Intervention: artemether-benflumetol
Number of subjects: 617

Group type: COMPARATOR
Intervention: artesunate-mefloquine
Number of subjects: 617
Study: 11990094

Group type: EXPERIMENTAL
Intervention: Cold water immersion at 18 degrees C
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cold water immersion at 26 degrees C
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cold water immersion at 22 degrees C
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cold water immersion (all temperatures)
Number of subjects: 24
Study: 2172393

Group type: EXPERIMENTAL
Intervention: Oka/Merck varicella vaccine (lot C-K472) with 950 pfu and relative antigen content of 1.0
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oka/Merck varicella vaccine with 1140 pfu/1.7 relative antigen or 1145 pfu/1.6 relative antigen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (Oka/Merck varicella vaccine with 950 pfu/1.0 relative antigen content)
Number of subjects: 0
Study: 367864

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isosorbide dinitrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30932775

Group type: EXPERIMENTAL
Intervention: Lutein complex supplementation (10 mg lutein, 500 mg ascorbic acid, 364 mg tocopherols, 2.5 mg carnosic acid, 2 mg zeaxanthin, 2 mg copper)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Lutein complex supplementation
Number of subjects: 16
Study: 30203770

Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0